Clinical Context
Hypoglycemia—blood glucose falling below normal levels—triggers a coordinated counterregulatory response designed to restore euglycemia. This defense system involves glucagon release from pancreatic alpha cells (the most important acute response), epinephrine and norepinephrine from the adrenal medulla, cortisol and growth hormone, and autonomic symptoms (sweating, tremor, palpitations) that alert patients to take corrective action. When this system fails, severe hypoglycemia can occur without warning.
Incretin-based therapies (GLP-1 agonists and the dual GIP/GLP-1 agonist tirzepatide) are often described as having low hypoglycemia risk because they enhance insulin secretion in a glucose-dependent manner. However, the effects of these drugs on counterregulatory responses to hypoglycemia—should it occur—are less studied. This matters because patients on incretins often also take insulin or sulfonylureas, which can cause hypoglycemia. Understanding how tirzepatide affects the counterregulatory response has important safety implications.
This study used the gold-standard hypoglycemic clamp technique, where glucose is lowered in a controlled manner to specific levels while measuring hormonal and symptomatic responses. This rigorous mechanistic design reveals how tirzepatide affects each component of the counterregulatory defense system.
Study Summary (PICO Framework)
Summary:
In adults with type 2 diabetes, 12 weeks of tirzepatide 15 mg weekly significantly reduced HbA1c by 1.5% while preserving glucagon response to hypoglycemia compared to placebo in a crossover design, but was associated with delayed cortisol and noradrenaline responses and reduced hypoglycemic symptom scores.
| PICO | Description |
|---|---|
| Population | Adults with T2DM (N=42) undergoing hypoglycemic clamp procedures in double-blind crossover design. |
| Intervention | Tirzepatide 15 mg weekly for 12 weeks before hypoglycemic clamp testing. |
| Comparison | Placebo for 12 weeks with 8-10 week wash-out between treatment periods. |
| Outcome | HbA1c: -1.5% vs +0.5%. Glucagon, GH, adrenaline responses preserved. Cortisol and noradrenaline delayed. Symptom scores reduced at nadir (p=0.007). Hypoglycemia awareness similar. |
Clinical Pearls
1. Glucagon response preservation is the key safety finding. Glucagon is the first-line defense against hypoglycemia, rapidly mobilizing hepatic glucose within minutes. The finding that tirzepatide preserves this response is reassuring—it means the most critical counterregulatory mechanism remains intact. This is consistent with incretins enhancing rather than replacing physiological glucose regulation.
2. Reduced symptom scores warrant attention. Patients on tirzepatide reported lower hypoglycemic symptom scores at the glucose nadir. This could mean reduced symptom awareness—a concerning finding if patients don’t recognize and treat hypoglycemia early. However, the study notes that overall hypoglycemia awareness was similar between groups, suggesting the effect may be subtle or context-dependent. The delayed cortisol and noradrenaline responses (which contribute to sympathetic symptoms) may explain the reduced symptom perception.
3. The delayed cortisol/noradrenaline responses have unclear clinical significance. While glucagon responds immediately to hypoglycemia, cortisol and catecholamines provide sustained counterregulation. Delayed responses might affect recovery from prolonged hypoglycemia. However, in real-world hypoglycemia (which is typically treated within minutes), the clinical impact may be minimal. More studies of spontaneous hypoglycemia in tirzepatide-treated patients would clarify real-world implications.
4. The crossover design provides robust within-subject comparison. Each participant served as their own control, eliminating between-subject variability in counterregulatory responses (which can be substantial). The 8-10 week washout ensures tirzepatide had cleared before the alternative treatment period. This rigorous design increases confidence in the findings.
Practical Application
Tirzepatide itself has low hypoglycemia risk: Like other incretins, tirzepatide’s glucose-dependent insulin secretion means hypoglycemia is rare in monotherapy or with metformin. The clinical relevance of this study primarily applies to patients also taking insulin or sulfonylureas, where hypoglycemia can occur independent of incretin effects.
Counsel patients on hypoglycemia recognition: Given the subtle finding of reduced symptom scores, remind patients on tirzepatide (especially those also on insulin or sulfonylureas) about hypoglycemia symptoms and the importance of prompt treatment. Consider CGM for patients at higher hypoglycemia risk, as continuous glucose data can detect hypoglycemia even if symptoms are reduced.
Reduce insulin doses when adding tirzepatide: Standard practice when adding potent incretins to insulin regimens is to proactively reduce insulin doses (typically by 10-20%) to prevent hypoglycemia as glucose improves. This becomes even more important if hypoglycemia awareness may be subtly affected. Sulfonylurea doses may also need reduction or discontinuation.
Don’t overinterpret this as a major safety concern: The overall pattern—preserved glucagon response, similar hypoglycemia awareness, primarily delayed rather than absent secondary responses—is reassuring. Tirzepatide remains a very effective therapy with a favorable safety profile. This mechanistic study adds nuance to our understanding but doesn’t fundamentally change the risk-benefit calculation.
How This Study Fits Into the Broader Evidence
Studies of GLP-1 receptor agonists have generally shown preserved counterregulatory responses to hypoglycemia, consistent with this tirzepatide finding. The glucose-dependent mechanism of incretin action—insulin secretion that shuts off as glucose falls—means these drugs don’t drive glucose below normal the way sulfonylureas or excess insulin can.
The finding of reduced symptom perception parallels some research on tight glycemic control, where patients who achieve very low HbA1c levels may have reduced symptom thresholds for hypoglycemia. Whether tirzepatide’s potent glucose-lowering contributes to this phenomenon (through generally lower glucose exposures) or whether there’s a direct drug effect remains unclear.
Clinical trial data from SURPASS and SURMOUNT programs show low rates of severe hypoglycemia with tirzepatide, especially without concomitant insulin or sulfonylureas. Real-world data as tirzepatide use expands will provide further insight into hypoglycemia patterns in diverse patient populations.
Limitations to Consider
The clamp-induced hypoglycemia is artificial—sustained, controlled, and predictable—differing from spontaneous hypoglycemic episodes which are briefer and more variable. The maximum dose (15 mg) was used; effects at lower doses may differ. Sample size (42 patients) is modest. The clinical significance of delayed rather than absent secondary responses remains unclear. Long-term effects on hypoglycemia awareness aren’t captured by this acute study.
Bottom Line
In this hypoglycemic clamp study, tirzepatide preserved the critical glucagon counterregulatory response to induced hypoglycemia in patients with type 2 diabetes, though cortisol and noradrenaline responses were delayed and hypoglycemic symptom scores were reduced. The findings are overall reassuring for tirzepatide’s safety profile, with the preservation of glucagon response being the most clinically relevant finding. However, when combining tirzepatide with insulin or sulfonylureas, remain vigilant about hypoglycemia risk and counsel patients on symptom recognition.
Source: Thomas R Pieber, et al. “Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.” Read article here.
